This site is intended for healthcare professionals
FDA warns against compounding semaglutide
The agency received reports of adverse events after some patients used compounded semaglutide. Thus, FDA warned against using compounded drugs when an approved drug is available. Patients and physicians are urged to understand that such products may contain salt forms and FDA does not review the safety and effectiveness of compounded versions of drugs.
FDA approves another SGTLT2 inhibitor for treating heart failure
INPEFA™ (sotagliflozin) is a once-daily oral pill meant for lowering the risk of hospitalization, emergency hospital visits, or death from heart failure in patients with heart failure, type 2 diabetes mellitus, kidney disease, and other heart-related risk factors. It is also indicated in full-range LVEF with preserved or reduced ejection fraction, with or without diabetes.
Bariatric surgery lowers the use of antidiabetic and lipid-lowering drugs
A study on more than 26,000 patients who had bariatric surgeries revealed that the usage of cardiovascular, lipid-lowering, and antidiabetic drugs was lower in the long-term in patients who underwent bariatric surgery compared to that in matched controls who did not undergo this surgery. However, the reduction was transient for cardiovascular medications.
FDA clears a new insulin pump and software for insulin delivery
Beta Bionics iLet ACE Pump, along with the iLet Dosing Decision Software, received FDA clearance for use in patients with type 1 diabetes aged 6 years and older. These two devices and an integrated CGM will combinedly become iLet Bionic Pancreas which uses a closed-loop algorithm to adjust insulin doses based on body weight, meal size, and amounts of carbohydrates.
Can PCOS affect the future generation of men's health?
Sons of women suffering from polycystic ovary syndrome are at double the risk of developing obesity, as per a study. They also had high levels of bad cholesterol, which raises the chances of insulin resistance and, in turn, type 2 diabetes in the future. These findings were also confirmed in studies on mice, highlighting the hidden risks of PCOS.
Another weight loss drug shows promising results in trials
Boehringer Ingelheim and Zealand Pharma reported that their obesity treatment caused 14.9% weight loss in a mid-stage clinical trial. It also met the primary goal in 46 weeks. The firms plan to start the last stage trial after a discussion with regulators. Meanwhile, Lilly's Mounjaro and Novo Nordisk's Wegovy caused 22.5% and 15 to 17% weight loss in the late-stage trials.
FDA extends the indication of dapagliflozin
This decision came after the findings from the DELIVER trial demonstrated positive effects by reducing hospitalization risk in heart failure across the spectrum of ejection fraction. Dapagliflozin was previously approved for type 2 diabetes, chronic kidney disease, and heart failure preserved ejection fraction. A similar decision was taken last year for empagliflozin.
AHA recommendations on fine-tuning Asian diets for heart health
An expert says that Asian Americans are prone to type 2 diabetes, which eventually affects the heart due to the high consumption of refined carbohydrates, low fiber intake, unhealthy fats, and high sodium. AHA advises adding more vegetables to stews, reducing sodium, using non-dairy alternatives, and replacing white rice with whole grains and coconut oil with healthy oils.
American Heart Association
New guidance to address bias and stigma in diagnosing obesity
The AACE's expert panel says obesity is an adiposity-based chronic disease. Its classification and nomenclature should be improved across BMI, waist circumference, and ethnic-specific BMI ranges. Staging ABCD's clinical severity based on complications could reduce stigma and bias, increasing the risk of psychological disorders and lowering the effectiveness of other therapies.
Bariatric surgery could help deal with peripheral neuropathy in diabetics
Bariatric surgery in obese patients with diabetes or those at risk of developing it can help regenerate peripheral nerves. Researchers found that nerve fibre density in the thigh region increased, and it remained stable in the legs two years after the surgery. These findings suggest a bariatric surgery could be a potential treatment option for peripheral neuropathy.